Treatment of cutaneous photoaging lesions with autologous platelet concentrate
Archives of Clinical Trials · 2022
DOI: 10.33425/2768-4598.1013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Clinical Trials, 2022. Verfasst von Yetter Cruz León und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Facial aging causes a devastating physical and mental impact on quality of life.
Objective
To evaluate the efficacy and safety of autologous platelet concentrate (APC) in the treatment of cutaneous photoaging (SCF).
Method
Between March 1, 2017 and March 31, 2021, at the “Hermanos Ameijeiras” hospital, a randomized, single-center, double-blind and controlled clinical trial was carried out in 164 patients with ECF. A group treated with CPA was compared to another treated with fresh autologous plasma (AFP). The treatment was applied monthly for 1 year.
Results
Three months after the end of the treatment, there were significant differences between the patients treated with CPA compared to those treated with PFA in terms of the improvement in the degree of photodamage and the degree of satisfaction (p
Zitieren
APA
León, Y. C., Trujillo, I. A., Novo, Y. L. M., Rojas, A. R. G., Campa, J. L. D. D. L., Silva, J. A. L., & Almaguer, D. S. (2022). Treatment of cutaneous photoaging lesions with autologous platelet concentrate. Archives of Clinical Trials. https://doi.org/10.33425/2768-4598.1013
Vancouver
León YC, Trujillo IA, Novo YLM, Rojas ARG, Campa JLDDL, Silva JAL, et al. Treatment of cutaneous photoaging lesions with autologous platelet concentrate. Archives of Clinical Trials. 2022. doi:10.33425/2768-4598.1013
BibTeX
@article{Len2022,
author = {León, Yetter Cruz and Trujillo, Israel Alfonso and Novo, Yaquelín Luciana Morales and Rojas, Angela Rosa Gutiérrez and Campa, Jesús Lazaro Diego De la and Silva, Julio Antonio López and Almaguer, Daymi Serpa},
title = {Treatment of cutaneous photoaging lesions with autologous platelet concentrate},
journal = {Archives of Clinical Trials},
year = {2022},
doi = {10.33425/2768-4598.1013}
}
EUVIMED